Literature DB >> 29254775

Efficient Interplay Effect Mitigation for Proton Pencil Beam Scanning by Spot-Adapted Layered Repainting Evenly Spread out Over the Full Breathing Cycle.

Per Rugaard Poulsen1, John Eley2, Ulrich Langner2, Charles B Simone2, Katja Langen2.   

Abstract

PURPOSE: To develop and implement a practical repainting method for efficient interplay effect mitigation in proton pencil beam scanning (PBS). METHODS AND MATERIALS: A new flexible repainting scheme with spot-adapted numbers of repainting evenly spread out over the whole breathing cycle (assumed to be 4 seconds) was developed. Twelve fields from 5 thoracic and upper abdominal PBS plans were delivered 3 times using the new repainting scheme to an ion chamber array on a motion stage. One time was static and 2 used 4-second, 3-cm peak-to-peak sinusoidal motion with delivery started at maximum inhalation and maximum exhalation. For comparison, all dose measurements were repeated with no repainting and with 8 repaintings. For each motion experiment, the 3%/3-mm gamma pass rate was calculated using the motion-convolved static dose as the reference. Simulations were first validated with the experiments and then used to extend the study to 0- to 5-cm motion magnitude, 2- to 6-second motion periods, patient-measured liver tumor motion, and 1- to 6-fraction treatments. The effect of the proposed method was evaluated for the 5 clinical cases using 4-dimensional (4D) dose reconstruction in the planning 4D computed tomography scan. The target homogeneity index, HI = (D2 - D98)/Dmean, of a single-fraction delivery is reported, where D2 and D98 is the dose delivered to 2% and 98% of the target, respectively, and Dmean is the mean dose.
RESULTS: The gamma pass rates were 59.6% ± 9.7% with no repainting, 76.5% ± 10.8% with 8 repaintings, and 92.4% ± 3.8% with the new repainting scheme. Simulations reproduced the experimental gamma pass rates with a 1.3% root-mean-square error and demonstrated largely improved gamma pass rates with the new repainting scheme for all investigated motion scenarios. One- and two-fraction deliveries with the new repainting scheme had gamma pass rates similar to those of 3-4 and 6-fraction deliveries with 8 repaintings. The mean HI for the 5 clinical cases was 14.2% with no repainting, 13.7% with 8 repaintings, 12.0% with the new repainting scheme, and 11.6% for the 4D dose without interplay effects.
CONCLUSIONS: A novel repainting strategy for efficient interplay effect mitigation was proposed, implemented, and shown to outperform conventional repainting in experiments, simulations, and dose reconstructions. This strategy could allow for safe and more optimal clinical delivery of thoracic and abdominal proton PBS and better facilitate hypofractionated and stereotactic treatments.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29254775     DOI: 10.1016/j.ijrobp.2017.09.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Treatment planning for proton therapy: what is needed in the next 10 years?

Authors:  Hakan Nystrom; Maria Fuglsang Jensen; Petra Witt Nystrom
Journal:  Br J Radiol       Date:  2019-08-07       Impact factor: 3.039

2.  Optimization of motion management parameters in a synchrotron-based spot scanning system.

Authors:  Jedediah E Johnson; Michael G Herman; Jon J Kruse
Journal:  J Appl Clin Med Phys       Date:  2019-09       Impact factor: 2.102

3.  The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.

Authors:  Luca Cozzi; Tiziana Comito; Mauro Loi; Antonella Fogliata; Ciro Franzese; Davide Franceschini; Elena Clerici; Giacomo Reggiori; Stefano Tomatis; Marta Scorsetti
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

4.  Investigating volumetric repainting to mitigate interplay effect on 4D robustly optimized lung cancer plans in pencil beam scanning proton therapy.

Authors:  Suresh Rana; Anatoly B Rosenfeld
Journal:  J Appl Clin Med Phys       Date:  2021-02-18       Impact factor: 2.102

Review 5.  Management of Motion and Anatomical Variations in Charged Particle Therapy: Past, Present, and Into the Future.

Authors:  Julia M Pakela; Antje Knopf; Lei Dong; Antoni Rucinski; Wei Zou
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

6.  Developing an accurate model of spot-scanning treatment delivery time and sequence for a compact superconducting synchrocyclotron proton therapy system.

Authors:  Lewei Zhao; Gang Liu; Shupeng Chen; Jiajian Shen; Weili Zheng; An Qin; Di Yan; Xiaoqiang Li; Xuanfeng Ding
Journal:  Radiat Oncol       Date:  2022-05-07       Impact factor: 4.309

Review 7.  Advances in proton therapy in lung cancer.

Authors:  Melissa A L Vyfhuis; Nasarachi Onyeuku; Tejan Diwanji; Sina Mossahebi; Neha P Amin; Shahed N Badiyan; Pranshu Mohindra; Charles B Simone
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

8.  Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma.

Authors:  Luca Cozzi; Tiziana Comito; Antonella Fogliata; Ciro Franzese; Stefano Tomatis; Marta Scorsetti
Journal:  PLoS One       Date:  2018-08-13       Impact factor: 3.240

9.  Dynamic gating window technique for the reduction of dosimetric error in respiratory-gated spot-scanning particle therapy: An initial phantom study using patient tumor trajectory data.

Authors:  Naoki Miyamoto; Kouhei Yokokawa; Seishin Takao; Taeko Matsuura; Sodai Tanaka; Shinichi Shimizu; Hiroki Shirato; Kikuo Umegaki
Journal:  J Appl Clin Med Phys       Date:  2020-02-18       Impact factor: 2.102

10.  Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy.

Authors:  Sheng Chang; Gang Liu; Lewei Zhao; Joshua T Dilworth; Weili Zheng; Saada Jawad; Di Yan; Peter Chen; Craig Stevens; Peyman Kabolizadeh; Xiaoqiang Li; Xuanfeng Ding
Journal:  Radiat Oncol       Date:  2020-10-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.